EUVIMEDEUVIMED entdecken
Crossref

Identification of FDA-Approved Drugs That Inhibit SARS-CoV-2 and Human Norovirus Replication

Tsuyoshi Hayashi, Junki Hirano, Kosuke Murakami, Yoshiki Fujii, Sakura Kobayashi, Takashi Tanikawa, Masashi Kitamura, Yuichi Someya

Biological and Pharmaceutical Bulletin · 2025

DOI: 10.1248/bpb.b25-00236 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Biological and Pharmaceutical Bulletin, 2025. Verfasst von Tsuyoshi Hayashi und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department of Virology II, National Institute of Infectious Diseases, 4-7-1 Gakuen, Musashimurayama, Tokyo 208-0011, Japan. Hauptthemen laut MEDLINE: Virus Replication, SARS-CoV-2, Antiviral Agents, Norovirus. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 26 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Kein Abstract verfügbar.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Virus ReplicationSARS-CoV-2Antiviral AgentsNorovirusCOVID-19 Drug TreatmentHumansUnited StatesUnited States Food and Drug AdministrationCoronavirus 3C ProteasesVero CellsChlorocebus aethiopsDrug ApprovalAnimalsDose-Response Relationship, Drug

Stichwörter der Autor:innen

FlipGFP assaycompound screenhuman norovirussevere acute respiratory syndrome coronavirus 2viral protease

Substanzen

Antiviral AgentsCoronavirus 3C Proteases3C-like proteinase, SARS-CoV-2

Autor:innen und Institutionen

  • Department of Virology II, National Institute of Infectious Diseases, 4-7-1 Gakuen, Musashimurayama, Tokyo 208-0011, Japan.
  • Laboratory of Viral Control, Research Institute for Microbial Diseases, Osaka University, 3-1 Yamadaoka, Suita, Osaka 565-0871, Japan.
  • Center for Emergency Preparedness and Response, National Institute of Infectious Diseases, 1-23-1 Toyama, Shinjuku-ku, Tokyo 162-8640, Japan.
  • School of Pharmacy, Faculty of Pharmacy and Pharmaceutical Sciences, Josai University, 1-1 Keyakidai, Sakado, Saitama 350-0295, Japan.

Zitieren

APA

Hayashi, T., Hirano, J., Murakami, K., Fujii, Y., Kobayashi, S., Tanikawa, T., Kitamura, M., & Someya, Y. (2025). Identification of FDA-Approved Drugs That Inhibit SARS-CoV-2 and Human Norovirus Replication. Biological and Pharmaceutical Bulletin. https://doi.org/10.1248/bpb.b25-00236

Vancouver

Hayashi T, Hirano J, Murakami K, Fujii Y, Kobayashi S, Tanikawa T, et al. Identification of FDA-Approved Drugs That Inhibit SARS-CoV-2 and Human Norovirus Replication. Biological and Pharmaceutical Bulletin. 2025. doi:10.1248/bpb.b25-00236

BibTeX
@article{Hayashi2025,
  author = {Hayashi, Tsuyoshi and Hirano, Junki and Murakami, Kosuke and Fujii, Yoshiki and Kobayashi, Sakura and Tanikawa, Takashi and Kitamura, Masashi and Someya, Yuichi},
  title = {Identification of FDA-Approved Drugs That Inhibit SARS-CoV-2 and Human Norovirus Replication},
  journal = {Biological and Pharmaceutical Bulletin},
  year = {2025},
  doi = {10.1248/bpb.b25-00236}
}
Kostenlos starten →